Drug Design Development and Therapy-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2091318, encodeId=e0e7209131820, content=偏重的研究方向：细胞;信号通路 经验分享：1F持续3天了，请问大家1F到2A一般几天？也没有收到邮件填作者贡献的表格，咋回事啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b058356108, createdName=ms1000000391690108, createdTime=Sat Oct 01 11:43:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100391, encodeId=0e572100391ef, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物 经验分享：投稿两个月，天然产物和临床药物的综述，说没有找到审稿人给退回来了，真的是莫名其妙啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89048177083, createdName=ms6000001309992242, createdTime=Mon Nov 14 10:48:10 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102658, encodeId=6062210265882, content=这个杂志封面都没有一个的吗？？！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92bb2184321, createdName=1207d69dm05暂无昵称, createdTime=Fri Nov 25 22:22:40 CST 2022, time=2022-11-25, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2100069, encodeId=8b90210006951, content=这个杂志必须要提供不剪膜的wb吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb2f8226933, createdName=ms9000000481856594, createdTime=Sat Nov 12 13:03:34 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097469, encodeId=c8ff209e46991, content=偏重的研究方向：药理 经验分享：本科生做的药效实验，离体巨噬细胞+动物水平+一点点机制（跑了蛋白），有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8588404260, createdName=ms6000001499010530, createdTime=Sun Oct 30 14:58:41 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243070, encodeId=2c1112430e0ea, content=偏重的研究方向：网药;药理;中药 经验分享：请问这个杂志网药+实验还收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Sun Sep 04 09:20:07 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209264, encodeId=0f2a1209264e2, content=偏重的研究方向：网药 经验分享：我在官网里看拒稿率2021到达68%，是不是很难投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:22:48 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092815, encodeId=6c9a209281575, content=偏重的研究方向：网药;药理 经验分享：动物实验需要提供人类伦理审批吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Oct 10 08:08:45 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209279, encodeId=007f12092e93d, content=请问这个是要所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:44:07 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089585, encodeId=bd832089585b3, content=偏重的研究方向：细胞;信号转导 经验分享：我是文章一作，请问大家1DA-WAITING FOR THIRD PARTY BILLING INFORMATION是什么意思？需要通讯作者操作什么吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0496546089, createdName=ms7000000950154870, createdTime=Wed Sep 21 17:43:36 CST 2022, time=2022-09-21, status=1, ipAttribution=)]

2022-10-01 ms1000000391690108

偏重的研究方向：细胞;信号通路
经验分享：1F持续3天了，请问大家1F到2A一般几天？也没有收到邮件填作者贡献的表格，咋回事啊

41 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2091318, encodeId=e0e7209131820, content=偏重的研究方向：细胞;信号通路 经验分享：1F持续3天了，请问大家1F到2A一般几天？也没有收到邮件填作者贡献的表格，咋回事啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b058356108, createdName=ms1000000391690108, createdTime=Sat Oct 01 11:43:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100391, encodeId=0e572100391ef, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物 经验分享：投稿两个月，天然产物和临床药物的综述，说没有找到审稿人给退回来了，真的是莫名其妙啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89048177083, createdName=ms6000001309992242, createdTime=Mon Nov 14 10:48:10 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102658, encodeId=6062210265882, content=这个杂志封面都没有一个的吗？？！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92bb2184321, createdName=1207d69dm05暂无昵称, createdTime=Fri Nov 25 22:22:40 CST 2022, time=2022-11-25, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2100069, encodeId=8b90210006951, content=这个杂志必须要提供不剪膜的wb吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb2f8226933, createdName=ms9000000481856594, createdTime=Sat Nov 12 13:03:34 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097469, encodeId=c8ff209e46991, content=偏重的研究方向：药理 经验分享：本科生做的药效实验，离体巨噬细胞+动物水平+一点点机制（跑了蛋白），有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8588404260, createdName=ms6000001499010530, createdTime=Sun Oct 30 14:58:41 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243070, encodeId=2c1112430e0ea, content=偏重的研究方向：网药;药理;中药 经验分享：请问这个杂志网药+实验还收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Sun Sep 04 09:20:07 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209264, encodeId=0f2a1209264e2, content=偏重的研究方向：网药 经验分享：我在官网里看拒稿率2021到达68%，是不是很难投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:22:48 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092815, encodeId=6c9a209281575, content=偏重的研究方向：网药;药理 经验分享：动物实验需要提供人类伦理审批吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Oct 10 08:08:45 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209279, encodeId=007f12092e93d, content=请问这个是要所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:44:07 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089585, encodeId=bd832089585b3, content=偏重的研究方向：细胞;信号转导 经验分享：我是文章一作，请问大家1DA-WAITING FOR THIRD PARTY BILLING INFORMATION是什么意思？需要通讯作者操作什么吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0496546089, createdName=ms7000000950154870, createdTime=Wed Sep 21 17:43:36 CST 2022, time=2022-09-21, status=1, ipAttribution=)]

2022-11-14 ms6000001309992242

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：药物
经验分享：投稿两个月，天然产物和临床药物的综述，说没有找到审稿人给退回来了，真的是莫名其妙啊

41 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2091318, encodeId=e0e7209131820, content=偏重的研究方向：细胞;信号通路 经验分享：1F持续3天了，请问大家1F到2A一般几天？也没有收到邮件填作者贡献的表格，咋回事啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b058356108, createdName=ms1000000391690108, createdTime=Sat Oct 01 11:43:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100391, encodeId=0e572100391ef, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物 经验分享：投稿两个月，天然产物和临床药物的综述，说没有找到审稿人给退回来了，真的是莫名其妙啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89048177083, createdName=ms6000001309992242, createdTime=Mon Nov 14 10:48:10 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102658, encodeId=6062210265882, content=这个杂志封面都没有一个的吗？？！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92bb2184321, createdName=1207d69dm05暂无昵称, createdTime=Fri Nov 25 22:22:40 CST 2022, time=2022-11-25, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2100069, encodeId=8b90210006951, content=这个杂志必须要提供不剪膜的wb吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb2f8226933, createdName=ms9000000481856594, createdTime=Sat Nov 12 13:03:34 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097469, encodeId=c8ff209e46991, content=偏重的研究方向：药理 经验分享：本科生做的药效实验，离体巨噬细胞+动物水平+一点点机制（跑了蛋白），有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8588404260, createdName=ms6000001499010530, createdTime=Sun Oct 30 14:58:41 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243070, encodeId=2c1112430e0ea, content=偏重的研究方向：网药;药理;中药 经验分享：请问这个杂志网药+实验还收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Sun Sep 04 09:20:07 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209264, encodeId=0f2a1209264e2, content=偏重的研究方向：网药 经验分享：我在官网里看拒稿率2021到达68%，是不是很难投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:22:48 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092815, encodeId=6c9a209281575, content=偏重的研究方向：网药;药理 经验分享：动物实验需要提供人类伦理审批吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Oct 10 08:08:45 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209279, encodeId=007f12092e93d, content=请问这个是要所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:44:07 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089585, encodeId=bd832089585b3, content=偏重的研究方向：细胞;信号转导 经验分享：我是文章一作，请问大家1DA-WAITING FOR THIRD PARTY BILLING INFORMATION是什么意思？需要通讯作者操作什么吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0496546089, createdName=ms7000000950154870, createdTime=Wed Sep 21 17:43:36 CST 2022, time=2022-09-21, status=1, ipAttribution=)]

2022-11-25 1207d69dm05暂无昵称来自广西

这个杂志封面都没有一个的吗？？！

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2091318, encodeId=e0e7209131820, content=偏重的研究方向：细胞;信号通路 经验分享：1F持续3天了，请问大家1F到2A一般几天？也没有收到邮件填作者贡献的表格，咋回事啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b058356108, createdName=ms1000000391690108, createdTime=Sat Oct 01 11:43:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100391, encodeId=0e572100391ef, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物 经验分享：投稿两个月，天然产物和临床药物的综述，说没有找到审稿人给退回来了，真的是莫名其妙啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89048177083, createdName=ms6000001309992242, createdTime=Mon Nov 14 10:48:10 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102658, encodeId=6062210265882, content=这个杂志封面都没有一个的吗？？！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92bb2184321, createdName=1207d69dm05暂无昵称, createdTime=Fri Nov 25 22:22:40 CST 2022, time=2022-11-25, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2100069, encodeId=8b90210006951, content=这个杂志必须要提供不剪膜的wb吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb2f8226933, createdName=ms9000000481856594, createdTime=Sat Nov 12 13:03:34 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097469, encodeId=c8ff209e46991, content=偏重的研究方向：药理 经验分享：本科生做的药效实验，离体巨噬细胞+动物水平+一点点机制（跑了蛋白），有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8588404260, createdName=ms6000001499010530, createdTime=Sun Oct 30 14:58:41 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243070, encodeId=2c1112430e0ea, content=偏重的研究方向：网药;药理;中药 经验分享：请问这个杂志网药+实验还收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Sun Sep 04 09:20:07 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209264, encodeId=0f2a1209264e2, content=偏重的研究方向：网药 经验分享：我在官网里看拒稿率2021到达68%，是不是很难投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:22:48 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092815, encodeId=6c9a209281575, content=偏重的研究方向：网药;药理 经验分享：动物实验需要提供人类伦理审批吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Oct 10 08:08:45 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209279, encodeId=007f12092e93d, content=请问这个是要所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:44:07 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089585, encodeId=bd832089585b3, content=偏重的研究方向：细胞;信号转导 经验分享：我是文章一作，请问大家1DA-WAITING FOR THIRD PARTY BILLING INFORMATION是什么意思？需要通讯作者操作什么吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0496546089, createdName=ms7000000950154870, createdTime=Wed Sep 21 17:43:36 CST 2022, time=2022-09-21, status=1, ipAttribution=)]

2022-11-12 ms9000000481856594

这个杂志必须要提供不剪膜的wb吗

41 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2091318, encodeId=e0e7209131820, content=偏重的研究方向：细胞;信号通路 经验分享：1F持续3天了，请问大家1F到2A一般几天？也没有收到邮件填作者贡献的表格，咋回事啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b058356108, createdName=ms1000000391690108, createdTime=Sat Oct 01 11:43:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100391, encodeId=0e572100391ef, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物 经验分享：投稿两个月，天然产物和临床药物的综述，说没有找到审稿人给退回来了，真的是莫名其妙啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89048177083, createdName=ms6000001309992242, createdTime=Mon Nov 14 10:48:10 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102658, encodeId=6062210265882, content=这个杂志封面都没有一个的吗？？！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92bb2184321, createdName=1207d69dm05暂无昵称, createdTime=Fri Nov 25 22:22:40 CST 2022, time=2022-11-25, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2100069, encodeId=8b90210006951, content=这个杂志必须要提供不剪膜的wb吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb2f8226933, createdName=ms9000000481856594, createdTime=Sat Nov 12 13:03:34 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097469, encodeId=c8ff209e46991, content=偏重的研究方向：药理 经验分享：本科生做的药效实验，离体巨噬细胞+动物水平+一点点机制（跑了蛋白），有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8588404260, createdName=ms6000001499010530, createdTime=Sun Oct 30 14:58:41 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243070, encodeId=2c1112430e0ea, content=偏重的研究方向：网药;药理;中药 经验分享：请问这个杂志网药+实验还收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Sun Sep 04 09:20:07 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209264, encodeId=0f2a1209264e2, content=偏重的研究方向：网药 经验分享：我在官网里看拒稿率2021到达68%，是不是很难投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:22:48 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092815, encodeId=6c9a209281575, content=偏重的研究方向：网药;药理 经验分享：动物实验需要提供人类伦理审批吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Oct 10 08:08:45 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209279, encodeId=007f12092e93d, content=请问这个是要所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:44:07 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089585, encodeId=bd832089585b3, content=偏重的研究方向：细胞;信号转导 经验分享：我是文章一作，请问大家1DA-WAITING FOR THIRD PARTY BILLING INFORMATION是什么意思？需要通讯作者操作什么吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0496546089, createdName=ms7000000950154870, createdTime=Wed Sep 21 17:43:36 CST 2022, time=2022-09-21, status=1, ipAttribution=)]

2022-10-30 ms6000001499010530

偏重的研究方向：药理
经验分享：本科生做的药效实验，离体巨噬细胞+动物水平+一点点机制（跑了蛋白），有希望吗

39 0

[GetPortalCommentsPageByObjectIdResponse(id=2091318, encodeId=e0e7209131820, content=偏重的研究方向：细胞;信号通路 经验分享：1F持续3天了，请问大家1F到2A一般几天？也没有收到邮件填作者贡献的表格，咋回事啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b058356108, createdName=ms1000000391690108, createdTime=Sat Oct 01 11:43:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100391, encodeId=0e572100391ef, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物 经验分享：投稿两个月，天然产物和临床药物的综述，说没有找到审稿人给退回来了，真的是莫名其妙啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89048177083, createdName=ms6000001309992242, createdTime=Mon Nov 14 10:48:10 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102658, encodeId=6062210265882, content=这个杂志封面都没有一个的吗？？！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92bb2184321, createdName=1207d69dm05暂无昵称, createdTime=Fri Nov 25 22:22:40 CST 2022, time=2022-11-25, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2100069, encodeId=8b90210006951, content=这个杂志必须要提供不剪膜的wb吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb2f8226933, createdName=ms9000000481856594, createdTime=Sat Nov 12 13:03:34 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097469, encodeId=c8ff209e46991, content=偏重的研究方向：药理 经验分享：本科生做的药效实验，离体巨噬细胞+动物水平+一点点机制（跑了蛋白），有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8588404260, createdName=ms6000001499010530, createdTime=Sun Oct 30 14:58:41 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243070, encodeId=2c1112430e0ea, content=偏重的研究方向：网药;药理;中药 经验分享：请问这个杂志网药+实验还收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Sun Sep 04 09:20:07 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209264, encodeId=0f2a1209264e2, content=偏重的研究方向：网药 经验分享：我在官网里看拒稿率2021到达68%，是不是很难投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:22:48 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092815, encodeId=6c9a209281575, content=偏重的研究方向：网药;药理 经验分享：动物实验需要提供人类伦理审批吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Oct 10 08:08:45 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209279, encodeId=007f12092e93d, content=请问这个是要所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:44:07 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089585, encodeId=bd832089585b3, content=偏重的研究方向：细胞;信号转导 经验分享：我是文章一作，请问大家1DA-WAITING FOR THIRD PARTY BILLING INFORMATION是什么意思？需要通讯作者操作什么吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0496546089, createdName=ms7000000950154870, createdTime=Wed Sep 21 17:43:36 CST 2022, time=2022-09-21, status=1, ipAttribution=)]

2022-09-04 ms5000001622730751

偏重的研究方向：网药;药理;中药
经验分享：请问这个杂志网药+实验还收吗

36 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2091318, encodeId=e0e7209131820, content=偏重的研究方向：细胞;信号通路 经验分享：1F持续3天了，请问大家1F到2A一般几天？也没有收到邮件填作者贡献的表格，咋回事啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b058356108, createdName=ms1000000391690108, createdTime=Sat Oct 01 11:43:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100391, encodeId=0e572100391ef, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物 经验分享：投稿两个月，天然产物和临床药物的综述，说没有找到审稿人给退回来了，真的是莫名其妙啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89048177083, createdName=ms6000001309992242, createdTime=Mon Nov 14 10:48:10 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102658, encodeId=6062210265882, content=这个杂志封面都没有一个的吗？？！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92bb2184321, createdName=1207d69dm05暂无昵称, createdTime=Fri Nov 25 22:22:40 CST 2022, time=2022-11-25, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2100069, encodeId=8b90210006951, content=这个杂志必须要提供不剪膜的wb吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb2f8226933, createdName=ms9000000481856594, createdTime=Sat Nov 12 13:03:34 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097469, encodeId=c8ff209e46991, content=偏重的研究方向：药理 经验分享：本科生做的药效实验，离体巨噬细胞+动物水平+一点点机制（跑了蛋白），有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8588404260, createdName=ms6000001499010530, createdTime=Sun Oct 30 14:58:41 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243070, encodeId=2c1112430e0ea, content=偏重的研究方向：网药;药理;中药 经验分享：请问这个杂志网药+实验还收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Sun Sep 04 09:20:07 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209264, encodeId=0f2a1209264e2, content=偏重的研究方向：网药 经验分享：我在官网里看拒稿率2021到达68%，是不是很难投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:22:48 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092815, encodeId=6c9a209281575, content=偏重的研究方向：网药;药理 经验分享：动物实验需要提供人类伦理审批吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Oct 10 08:08:45 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209279, encodeId=007f12092e93d, content=请问这个是要所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:44:07 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089585, encodeId=bd832089585b3, content=偏重的研究方向：细胞;信号转导 经验分享：我是文章一作，请问大家1DA-WAITING FOR THIRD PARTY BILLING INFORMATION是什么意思？需要通讯作者操作什么吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0496546089, createdName=ms7000000950154870, createdTime=Wed Sep 21 17:43:36 CST 2022, time=2022-09-21, status=1, ipAttribution=)]

2022-04-07 ms3000001008861272

偏重的研究方向：网药
经验分享：我在官网里看拒稿率2021到达68%，是不是很难投

51 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2091318, encodeId=e0e7209131820, content=偏重的研究方向：细胞;信号通路 经验分享：1F持续3天了，请问大家1F到2A一般几天？也没有收到邮件填作者贡献的表格，咋回事啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b058356108, createdName=ms1000000391690108, createdTime=Sat Oct 01 11:43:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100391, encodeId=0e572100391ef, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物 经验分享：投稿两个月，天然产物和临床药物的综述，说没有找到审稿人给退回来了，真的是莫名其妙啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89048177083, createdName=ms6000001309992242, createdTime=Mon Nov 14 10:48:10 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102658, encodeId=6062210265882, content=这个杂志封面都没有一个的吗？？！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92bb2184321, createdName=1207d69dm05暂无昵称, createdTime=Fri Nov 25 22:22:40 CST 2022, time=2022-11-25, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2100069, encodeId=8b90210006951, content=这个杂志必须要提供不剪膜的wb吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb2f8226933, createdName=ms9000000481856594, createdTime=Sat Nov 12 13:03:34 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097469, encodeId=c8ff209e46991, content=偏重的研究方向：药理 经验分享：本科生做的药效实验，离体巨噬细胞+动物水平+一点点机制（跑了蛋白），有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8588404260, createdName=ms6000001499010530, createdTime=Sun Oct 30 14:58:41 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243070, encodeId=2c1112430e0ea, content=偏重的研究方向：网药;药理;中药 经验分享：请问这个杂志网药+实验还收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Sun Sep 04 09:20:07 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209264, encodeId=0f2a1209264e2, content=偏重的研究方向：网药 经验分享：我在官网里看拒稿率2021到达68%，是不是很难投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:22:48 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092815, encodeId=6c9a209281575, content=偏重的研究方向：网药;药理 经验分享：动物实验需要提供人类伦理审批吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Oct 10 08:08:45 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209279, encodeId=007f12092e93d, content=请问这个是要所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:44:07 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089585, encodeId=bd832089585b3, content=偏重的研究方向：细胞;信号转导 经验分享：我是文章一作，请问大家1DA-WAITING FOR THIRD PARTY BILLING INFORMATION是什么意思？需要通讯作者操作什么吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0496546089, createdName=ms7000000950154870, createdTime=Wed Sep 21 17:43:36 CST 2022, time=2022-09-21, status=1, ipAttribution=)]

2022-10-10 ms5000000678442882

偏重的研究方向：网药;药理
经验分享：动物实验需要提供人类伦理审批吗

38 0

[GetPortalCommentsPageByObjectIdResponse(id=2091318, encodeId=e0e7209131820, content=偏重的研究方向：细胞;信号通路 经验分享：1F持续3天了，请问大家1F到2A一般几天？也没有收到邮件填作者贡献的表格，咋回事啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b058356108, createdName=ms1000000391690108, createdTime=Sat Oct 01 11:43:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100391, encodeId=0e572100391ef, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物 经验分享：投稿两个月，天然产物和临床药物的综述，说没有找到审稿人给退回来了，真的是莫名其妙啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89048177083, createdName=ms6000001309992242, createdTime=Mon Nov 14 10:48:10 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102658, encodeId=6062210265882, content=这个杂志封面都没有一个的吗？？！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92bb2184321, createdName=1207d69dm05暂无昵称, createdTime=Fri Nov 25 22:22:40 CST 2022, time=2022-11-25, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2100069, encodeId=8b90210006951, content=这个杂志必须要提供不剪膜的wb吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb2f8226933, createdName=ms9000000481856594, createdTime=Sat Nov 12 13:03:34 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097469, encodeId=c8ff209e46991, content=偏重的研究方向：药理 经验分享：本科生做的药效实验，离体巨噬细胞+动物水平+一点点机制（跑了蛋白），有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8588404260, createdName=ms6000001499010530, createdTime=Sun Oct 30 14:58:41 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243070, encodeId=2c1112430e0ea, content=偏重的研究方向：网药;药理;中药 经验分享：请问这个杂志网药+实验还收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Sun Sep 04 09:20:07 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209264, encodeId=0f2a1209264e2, content=偏重的研究方向：网药 经验分享：我在官网里看拒稿率2021到达68%，是不是很难投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:22:48 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092815, encodeId=6c9a209281575, content=偏重的研究方向：网药;药理 经验分享：动物实验需要提供人类伦理审批吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Oct 10 08:08:45 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209279, encodeId=007f12092e93d, content=请问这个是要所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:44:07 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089585, encodeId=bd832089585b3, content=偏重的研究方向：细胞;信号转导 经验分享：我是文章一作，请问大家1DA-WAITING FOR THIRD PARTY BILLING INFORMATION是什么意思？需要通讯作者操作什么吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0496546089, createdName=ms7000000950154870, createdTime=Wed Sep 21 17:43:36 CST 2022, time=2022-09-21, status=1, ipAttribution=)]

2022-04-07 ms3000001008861272

请问这个是要所有的原始数据吗

52 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2091318, encodeId=e0e7209131820, content=偏重的研究方向：细胞;信号通路 经验分享：1F持续3天了，请问大家1F到2A一般几天？也没有收到邮件填作者贡献的表格，咋回事啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b058356108, createdName=ms1000000391690108, createdTime=Sat Oct 01 11:43:52 CST 2022, time=2022-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100391, encodeId=0e572100391ef, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物 经验分享：投稿两个月，天然产物和临床药物的综述，说没有找到审稿人给退回来了，真的是莫名其妙啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89048177083, createdName=ms6000001309992242, createdTime=Mon Nov 14 10:48:10 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102658, encodeId=6062210265882, content=这个杂志封面都没有一个的吗？？！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92bb2184321, createdName=1207d69dm05暂无昵称, createdTime=Fri Nov 25 22:22:40 CST 2022, time=2022-11-25, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2100069, encodeId=8b90210006951, content=这个杂志必须要提供不剪膜的wb吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb2f8226933, createdName=ms9000000481856594, createdTime=Sat Nov 12 13:03:34 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097469, encodeId=c8ff209e46991, content=偏重的研究方向：药理 经验分享：本科生做的药效实验，离体巨噬细胞+动物水平+一点点机制（跑了蛋白），有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8588404260, createdName=ms6000001499010530, createdTime=Sun Oct 30 14:58:41 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243070, encodeId=2c1112430e0ea, content=偏重的研究方向：网药;药理;中药 经验分享：请问这个杂志网药+实验还收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Sun Sep 04 09:20:07 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209264, encodeId=0f2a1209264e2, content=偏重的研究方向：网药 经验分享：我在官网里看拒稿率2021到达68%，是不是很难投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:22:48 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092815, encodeId=6c9a209281575, content=偏重的研究方向：网药;药理 经验分享：动物实验需要提供人类伦理审批吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Oct 10 08:08:45 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209279, encodeId=007f12092e93d, content=请问这个是要所有的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55b75617721, createdName=ms3000001008861272, createdTime=Thu Apr 07 16:44:07 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089585, encodeId=bd832089585b3, content=偏重的研究方向：细胞;信号转导 经验分享：我是文章一作，请问大家1DA-WAITING FOR THIRD PARTY BILLING INFORMATION是什么意思？需要通讯作者操作什么吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0496546089, createdName=ms7000000950154870, createdTime=Wed Sep 21 17:43:36 CST 2022, time=2022-09-21, status=1, ipAttribution=)]

2022-09-21 ms7000000950154870

偏重的研究方向：细胞;信号转导
经验分享：我是文章一作，请问大家1DA-WAITING FOR THIRD PARTY BILLING INFORMATION是什么意思？需要通讯作者操作什么吗

27 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务